The FDA is investigating the death of an 8-year-old boy who received Elevidys, a gene therapy for Duchenne muscular dystrophy. Sarepta Therapeutics voluntarily suspended product distribution while safety concerns are investigated, stating the death was unrelated to treatment. Elevidys is a gene therapy using AAVrh74 Platform Technology for Duchenne muscular dystrophy. Duchenne muscular dystrophy is a rare genetic condition causing progressive muscular weakness. Roche Holding AG confirmed a patient’s death in Brazil after Elevidys treatment was unrelated to the therapy. SRPT stock closed down 7.29% after the news.

Read more at Nasdaq: FDA Investigates Child’s Death After Receiving Sarepta’s Elevidys Gene Therapy